Nucleoside conjugates of quantum dots for characterization of G protein-coupled receptors: strategies for immobilizing A2A adenosine receptor agonists

BackgroundQuantum dots (QDs) are crystalline nanoparticles that are compatible with biological systems to provide a chemically and photochemically stable fluorescent label. New ligand probes with fluorescent reporter groups are needed for detection and characterization of G protein-coupled receptors (GPCRs).ResultsSynthetic strategies for coupling the A2A adenosine receptor (AR) agonist CGS21680 (2-[4-(2-carboxyethyl)phenylethylamino]-5'-N-ethylcarboxamidoadenosine) to functionalized QDs were explored. Conjugates tethered through amide-linked chains and poly(ethyleneglycol) (PEG) displayed low solubility and lacked receptor affinity. The anchor to the dendron was either through two thiol groups of (R)-thioctic acid or through amide formation to a commercial carboxy-derivatized QD. The most effective approach was to use polyamidoamine (PAMAM) D5 dendrons as multivalent spacer groups, grafted on the QD surface through a thioctic acid moiety. In radioligand binding assays, dendron nucleoside conjugate 11 displayed a moderate affinity at the human A2AAR (Kiapp 1.02 ± 0.15 μM). The QD conjugate of increased water solubility 13, resulting from the anchoring of this dendron derivative, interacted with the receptor with Kiapp of 118 ± 54 nM. The fluorescence emission of 13 occurred at 565 nm, and the presence of the pendant nucleoside did not appreciably quench the fluorescence.ConclusionsThis is a feasibility study to demonstrate a means of conjugating to a QD a small molecular pharmacophore of a GPCR that is relatively hydrophobic. Further enhancement of affinity by altering the pharmacophore or the linking structures will be needed to make useful affinity probes.

[1]  K. Jacobson Functionalized congener approach to the design of ligands for G protein-coupled receptors (GPCRs). , 2009, Bioconjugate chemistry.

[2]  P. Seeberger,et al.  In vitro imaging and in vivo liver targeting with carbohydrate capped quantum dots. , 2009, Journal of the American Chemical Society.

[3]  O. Manzoni,et al.  Altered surface trafficking of presynaptic cannabinoid type 1 receptor in and out synaptic terminals parallels receptor desensitization , 2008, Proceedings of the National Academy of Sciences.

[4]  K. Jacobson,et al.  PEGylated dendritic unimolecular micelles as versatile carriers for ligands of G protein-coupled receptors. , 2009, Bioconjugate chemistry.

[5]  M. Vaultier,et al.  Reduction d'azides en amines primaires par une methode generale utilisant la reaction de staudinger , 1983 .

[6]  Hong Ding,et al.  Biocompatible near-infrared quantum dots as ultrasensitive probes for long-term in vivo imaging applications. , 2009, Small.

[7]  Sanjiv S Gambhir,et al.  Cys-diabody quantum dot conjugates (immunoQdots) for cancer marker detection. , 2009, Bioconjugate chemistry.

[8]  Igor L. Medintz,et al.  Enhancing the stability and biological functionalities of quantum dots via compact multifunctional ligands. , 2007, Journal of the American Chemical Society.

[9]  M. Williams,et al.  [3H]CGS 21680, a selective A2 adenosine receptor agonist directly labels A2 receptors in rat brain. , 1989, The Journal of pharmacology and experimental therapeutics.

[10]  Moungi G Bawendi,et al.  Compact biocompatible quantum dots functionalized for cellular imaging. , 2008, Journal of the American Chemical Society.

[11]  I. Texier,et al.  In vivo imaging of quantum dots. , 2009, Methods in molecular biology.

[12]  K. Jacobson,et al.  "Reversine" and its 2-substituted adenine derivatives as potent and selective A3 adenosine receptor antagonists. , 2005, Journal of medicinal chemistry.

[13]  Sandra J Rosenthal,et al.  Universal polyethylene glycol linkers for attaching receptor ligands to quantum dots. , 2006, Bioorganic & medicinal chemistry letters.

[14]  Donald A. Tomalia,et al.  In quest of a systematic framework for unifying and defining nanoscience. , 2012, Journal of nanoparticle research : an interdisciplinary forum for nanoscale science and technology.

[15]  V. Torchilin,et al.  Quantum dots encapsulated in phospholipid micelles for imaging and quantification of tumors in the near-infrared region. , 2009, Nanomedicine : nanotechnology, biology, and medicine.

[16]  Igor L. Medintz,et al.  Quantum dot bioconjugates for imaging, labelling and sensing , 2005, Nature materials.

[17]  B. Weimer,et al.  Optimizing the immobilization of single-stranded DNA onto glass beads. , 2001, Journal of biochemical and biophysical methods.

[18]  D. Yee,et al.  Fluorescent tumour imaging of type I IGF receptor in vivo: comparison of antibody-conjugated quantum dots and small-molecule fluorophore , 2009, British Journal of Cancer.

[19]  K. Jacobson,et al.  Adenosine receptors as therapeutic targets , 2006, Nature Reviews Drug Discovery.

[20]  Rafael A. Khatchadourian,et al.  Fluorescence Intensity and Intermittency as Tools for Following Dopamine Bioconjugate Processing in Living Cells , 2008, Journal of biomedicine & biotechnology.

[21]  G. Ellman,et al.  Tissue sulfhydryl groups. , 1959, Archives of biochemistry and biophysics.

[22]  R. Stevens,et al.  The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist , 2008, Science.

[23]  E. Rossinyol,et al.  QDs versus Alexa: reality of promising tools for immunocytochemistry , 2009, Journal of nanobiotechnology.

[24]  M. M. Bradford A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[25]  A. R. Williams,et al.  Relative fluorescence quantum yields using a computer-controlled luminescence spectrometer , 1983 .

[26]  K. Jacobson,et al.  Toward multivalent signaling across G protein-coupled receptors from poly(amidoamine) dendrimers. , 2008, Bioconjugate chemistry.

[27]  Y. Nodasaka,et al.  Control of the optical properties of quantum dots by surface coating with calix[n]arene carboxylic acids. , 2006, Journal of the American Chemical Society.

[28]  Jianghong Rao,et al.  Quantum dot bioconjugates for in vitro diagnostics & in vivo imaging. , 2008, Cancer biomarkers : section A of Disease markers.

[29]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[30]  Beverly A Rzigalinski,et al.  Cadmium-containing nanoparticles: perspectives on pharmacology and toxicology of quantum dots. , 2009, Toxicology and applied pharmacology.

[31]  Min Zhou,et al.  Peptide-labeled quantum dots for imaging GPCRs in whole cells and as single molecules. , 2007, Bioconjugate chemistry.

[32]  L. Pannell,et al.  Agonist derived molecular probes for A2 adenosine receptors , 1989, Journal of molecular recognition : JMR.

[33]  K. Jacobson,et al.  Enhanced potency of nucleotide-dendrimer conjugates as agonists of the P2Y14 receptor: multivalent effect in G protein-coupled receptor recognition. , 2009, Bioconjugate chemistry.

[34]  Hak Soo Choi,et al.  Tissue- and organ-selective biodistribution of NIR fluorescent quantum dots. , 2009, Nano letters.

[35]  K. Jacobson,et al.  Enhanced A3 adenosine receptor selectivity of multivalent nucleoside-dendrimer conjugates , 2008, Journal of nanobiotechnology.

[36]  M. R. Imam,et al.  Dendron-mediated self-assembly, disassembly, and self-organization of complex systems. , 2009, Chemical reviews.